The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
J Infect Dis
; 225(6): 934-937, 2022 03 15.
Article
in English
| MEDLINE | ID: covidwho-1740886
ABSTRACT
The world's first coronavirus disease 2019 human challenge trial using the D614G strain of severe acute respiratory syndrome 2 (SARS-CoV-2) is underway in the United Kingdom. The Wellcome Trust is funding challenge stock preparation of the Beta and Delta variant for a follow-up human challenge trial, and researchers at hVIVO are considering conducting these trials. However, little has been written thus far about the ethical justifiability of human challenge trials with SARS-CoV-2 variants of concern. We explore 2 specific characteristics of some variants that may initially be thought to make such trials unethical and conclude that SARS-CoV-2 variant challenge trials can remain ethical.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Ethics, Research
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
/
Variants
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
J Infect Dis
Year:
2022
Document Type:
Article
Affiliation country:
Infdis
Similar
MEDLINE
...
LILACS
LIS